RAPT Therapeutics, Inc. (RAPT)

8.12 -0.06 (-0.67%) At close: 04:00PM EDT

RAPT Therapeutics, Inc.

561 Eccles Avenue
South San Francisco, CA 94080
United States
650 489 9000
https://www.rapt.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 131

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Brian Russell Wong M.D., Ph.D.	CEO, President & Director	861.24k	N/A	1972
Mr. Rodney K. B. Young	CFO, Principal Accounting Officer & Secretary	616.56k	N/A	1963
Dr. William Ho M.D., Ph.D.	Chief Medical Officer	620.32k	N/A	1966
Steve Young Ph.D.	Vice President of Technology	N/A	N/A	N/A
Dr. Dirk G. Brockstedt Ph.D.	Chief Scientific Officer	490.25k	N/A	1969
Mr. Michael Listgarten	General Counsel	N/A	N/A	N/A
Ms. Gwen R. Carscadden	Chief Human Resources Officer	N/A	N/A	1961
Dr. Paul Kassner	Senior Vice President of Quantitative & Computational Biology	N/A	N/A	1967
Dr. David Wustrow	Senior Vice President of Drug Discovery & Preclinical Development	N/A	N/A	1959
Ms. Jennifer Nicholson	Senior Vice President of Regulatory Affairs & Quality Assurance	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Corporate governance

RAPT Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 6; Board: 6; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.